オプションチェーンは、AbbVieの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、AbbVieの市場センチメントを評価します。.

AbbVie (NYSE:ABBV) 株価情報, オプションチェーン

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie Inc

ABBVIE ORD

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $212 to $221.

News

Price Target

Analyst Ratings

ABBV

Guggenheim Maintains Buy on AbbVie, Raises Price Target to $221

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 11 unusual trades.
Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $454,486, and 5 were calls, valued at $292,034.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $195.0 and $210.0 for AbbVie, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for AbbVie options trades today is 559.88 with a total volume of 4,547.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for AbbVie's big money trades within a strike price range of $195.0 to $210.0 over the last 30 days.
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730915232_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$1.88</td>
<td>$1.89</td>
<td>$1.89</td>
<td>$207.50</td>
<td>$163.1K</td>
<td style="text-align: right;">223</td>
<td>868</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.11</td>
<td>$1.78</td>
<td>$2.11</td>
<td>$197.50</td>
<td>$162.2K</td>
<td style="text-align: right;">1</td>
<td>781</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$2.25</td>
<td>$1.91</td>
<td>$2.25</td>
<td>$200.00</td>
<td>$78.7K</td>
<td style="text-align: right;">269</td>
<td>245</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$11.4</td>
<td>$11.25</td>
<td>$11.4</td>
<td>$200.00</td>
<td>$67.2K</td>
<td style="text-align: right;">53</td>
<td>60</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$1.66</td>
<td>$1.59</td>
<td>$1.66</td>
<td>$197.50</td>
<td>$52.2K</td>
<td style="text-align: right;">1</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,248,728, the price of ABBV is up by 0.19%, reaching $202.07.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>Expert Opinions on AbbVie</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $217.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $231. 
&#x2A; An analyst from Citigroup persists with their Buy rating on AbbVie, maintaining a target price of $226. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on AbbVie with a target price of $215. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on AbbVie, which currently sits at a price target of $220. 
&#x2A; An analyst from UBS persists with their Neutral rating on AbbVie, maintaining a target price of $195. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

What the Options Market Tells Us About AbbVie

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.39% on an annualized basis producing an average annual return of 12.18%. Currently, AbbVie has a market capitalization of $360.24 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $315.90 today based on a price of $204.00 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730741416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today

Argus Research analyst David Toung upgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Hold to Buy.

Upgrades

Argus Research Upgrades AbbVie to Buy

In the current session, the stock is trading at $201.74, after a 6.49% spike. Over the past month, AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock increased by 4.84%, and in the past year, by 44.26%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730477716_0.png" alt="Past Year Chart" />

<h3>Comparing AbbVie P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
AbbVie has a lower P/E than the aggregate P/E of 112.06 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730477716_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: AbbVie

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $215 to $226.

Citigroup Maintains Buy on AbbVie, Raises Price Target to $226

UBS analyst Navin Jacob maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and raises the price target from $195 to $200.

UBS Maintains Neutral on AbbVie, Raises Price Target to $200

In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>AbbVie Background</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>70.21</td>
<td>52.51</td>
<td>6.43</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>40.33</td>
<td>22.57</td>
<td>5.24</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>107.66</td>
<td>6.01</td>
<td>3.97</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>24.43</td>
<td>3.61</td>
<td>7.83</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>16.38</td>
<td>1.61</td>
<td>2.75</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>15.86</td>
<td>2.64</td>
<td>6.40</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>18.43</td>
<td>3.19</td>
<td>5.37</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>821.56</td>
<td>4.49</td>
<td>3.91</td>
<td>3.45%</td>
<td>$0.18</td>
<td>$1.05</td>
<td>23.81%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>40.17</td>
<td>2.35</td>
<td>4.67</td>
<td>1.98%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>4.73%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>33.15</td>
<td>4.63</td>
<td>5.74</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>170.26</td>
<td>11.31</td>
<td>8.29</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>20.92</td>
<td>4.07</td>
<td>4.69</td>
<td>5.37%</td>
<td>$0.2</td>
<td>$0.52</td>
<td>14.33%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.06</td>
<td>1.60</td>
<td>62.26</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Average</td>
<td>109.27</td>
<td>5.67</td>
<td>10.09</td>
<td>4.74%</td>
<td>$1.0</td>
<td>$2.04</td>
<td>29.56%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a meticulous analysis of AbbVie, we can observe the following trends: 
<ul>
<li>
A Price to Earnings ratio of 70.21 significantly below the industry average by 0.64x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
The elevated Price to Book ratio of 52.51 relative to the industry average by 9.26x suggests company might be overvalued based on its book value.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 6.43, which is 0.64x the industry average.
</li>
<li>
The Return on Equity (ROE) of 18.4% is 13.66% above the industry average, highlighting efficient use of equity to generate profits.
</li>
<li>
The company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.0x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
The gross profit of $10.26 Billion is 5.03x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 4.31% compared to the industry average of 29.56%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730386850_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating AbbVie alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
<ul>
<li>
AbbVie holds a middle position in terms of the debt-to-equity ratio compared to its top 4 peers.
</li>
<li>
This indicates a balanced financial structure with a moderate level of debt and an appropriate reliance on equity financing with a debt-to-equity ratio of 10.42.
</li>
</ul>
<h3>Key Takeaways</h3>
For AbbVie in the Biotechnology industry, the PE ratio is low compared to peers, indicating potential undervaluation. The high PB ratio suggests the market values AbbVie's assets highly. A low PS ratio implies sales are relatively low compared to market capitalization. AbbVie's high ROE, EBITDA, and gross profit reflect strong profitability and operational efficiency. However, the low revenue growth may indicate challenges in expanding market share compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market Analysis: AbbVie And Competitors In Biotechnology Industry

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $218 to $231.

Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $231

Contracts

AbbVie, EvolveImmune Therapeutics Announce Option-To-License Agreement; EvolveImmune To Receive $65M In Aggregate Upfront Fees And Equity Investment From AbbVie; AbbVie Eligible For Up To $1.4B In Option Fees, Milestones

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

Analyst Color

Biotech

Equities

Large Cap

Health Care

General

AMGN

BIIB

CATX

INCY

KYMR

REGN

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41623984/us-economy-grows-less-than-expected-in-q3-yet-private-employment-soars-by-233-000">and fresh economic data.</a>
The U.S. economy grew at an annualized rate of 2.8% in the third quarter, according to advance estimates. This marks a slight deceleration from the previous quarter's 3% pace and falls short of analyst expectations of 3%.
On the employment front, the ADP National Employment report showed private payrolls surged by 233,000 in October —well above the 115,000 forecast and a significant increase from the revised 159,000 in September. This stronger-than-expected job growth underscores the resilience of the labor market ahead of Friday&#8217;s official jobs report.
In corporate news, Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) dropped 10% after posting quarterly results that met expectations but failed to excite investors. The decline in AMD shares dragged down the broader semiconductor sector, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) sliding over 3%.
In contrast, Alphabet Inc. jumped more than 5% following a robust earnings report that beat Wall Street expectations, boosting optimism around mega-cap tech stocks.
At midday, major U.S. indexes were trading mixed. The S&amp;P 500 and the tech-heavy Nasdaq 100 remained flat, while the small-cap Russell 2000 outperformed with a 0.5% gain.
Gold prices extended all-time highs, up 0.5% to $2,787 per ounce. Oil prices surged 2%, fueled by supply concerns.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased 0.8% to $72,100, pulling back from recent highs.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,246.40</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,309.80</td>
<td>0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,838.86</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,505.98</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103024&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.1% higher to $582.16.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.2% to $423.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.2% to $499.18.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $222.76.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up by 1.3%. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 0.9%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) tumbled 33% after auditors Ernst &amp; Young announced their resignation amid reporting issues, five days ahead of the company&#8217;s earnings report. </li>
</ul>
Large-cap stocks reacting to earnings were:
<ul>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), down 8%, </li>
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), up 3.6%, </li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) up over 5%, </li>
<li>Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), down 1.4%, </li>
<li>Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), down 1%,</li>
<li>Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), up 1%, </li>
<li>Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), down over 7%, </li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), up 15%,</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>), up 38%, </li>
<li>Automatic Data Processing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>), up 1%, </li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>), up 24%. </li>
</ul>
Major companies reporting earnings after the close Wednesday include Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41629264/alphabets-earnings-rally-pushes-magnificent-7-market-cap-to-record-16-8-trillion-10-tech-heavy-e">Alphabet&#8217;s Earnings Rally Pushes Magnificent 7 Market Cap To Record $16.8 Trillion: 10 Tech-Heavy ETFs Moving Wednesday</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Movers

Tech

ETFs

$BTC

BKNG

SPDR Dow Jones Industrial Average ETF Trust

GRMN

MDLZ

MSFT

RDDT

SMCI

SNAP

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?

Deep-pocketed investors have adopted a bullish approach towards AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABBV usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for AbbVie. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 5 are puts, totaling $278,297, and 5 are calls, amounting to $313,414.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $210.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AbbVie stands at 2210.14, with a total volume reaching 6,502.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $180.0 to $210.0, throughout the last 30 days.
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730302233_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.4</td>
<td>$2.03</td>
<td>$2.4</td>
<td>$185.00</td>
<td>$120.0K</td>
<td>3.2K</td>
<td style="text-align: right;">504</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.35</td>
<td>$7.3</td>
<td>$7.35</td>
<td>$190.00</td>
<td>$90.4K</td>
<td>3.2K</td>
<td style="text-align: right;">254</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$1.91</td>
<td>$1.7</td>
<td>$1.9</td>
<td>$192.50</td>
<td>$86.3K</td>
<td>568</td>
<td style="text-align: right;">665</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.63</td>
<td>$2.59</td>
<td>$2.59</td>
<td>$210.00</td>
<td>$68.1K</td>
<td>1.8K</td>
<td style="text-align: right;">293</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.28</td>
<td>$1.98</td>
<td>$2.28</td>
<td>$185.00</td>
<td>$57.0K</td>
<td>3.2K</td>
<td style="text-align: right;">754</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Current Position of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 1,914,806, the ABBV's price is up by 1.5%, now at $192.3. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Expert Opinions on AbbVie</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $214.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for AbbVie, targeting a price of $215. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for AbbVie, targeting a price of $195. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on AbbVie, maintaining a target price of $215. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $225. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on AbbVie with a target price of $220. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

AbbVie's Options Frenzy: What You Need to Know

WIIM

AbbVie shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

On Wednesday,&nbsp;AbbVie Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.92</a>.
Net revenues reached $14.46 billion, up 3.8%, beating the&nbsp;consensus of $14.28 billion. Sales were up&nbsp;4.9% <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41621806/abbvie-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">on an operational basis</a>.
The immunology portfolio generated&nbsp;$7.05 billion&nbsp;in sales, up 3.9% on a reported basis or 4.8% on an operational basis.
<ul>
<li>Humira revenues were $2.23 billion (down 37.2%), Skyrizi sales reached $3.21 billion (up 50.8%), and Rinvoq revenues were $1.61 billion (up 45.3%).&nbsp;</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384990/fda-approves-abbvies-parkinsons-treatment-medicare-coverage-expected-next-year" rel="noreferrer noopener">FDA Approves AbbVie&#8217;s Parkinson&#8217;s Treatment, Medicare Coverage Expected Next Year</a>
Oncology product sales were&nbsp;$1.69 billion, up 11.6% or 13.0% on an operational basis.
<ul>
<li>Imbruvica revenues were $828 million (down 8.8%), Venclexta sales increased 14.8% to $677 million, and Elahere's net revenues were&nbsp;$139 million.</li>
</ul>
Neuroscience revenues reached $2.36 billion, up 15.6% on a reported basis or 16.0% on an operational basis.
<ul>
<li>Botox Therapeutic sales were&nbsp;$848 million, up 13.4%. Aesthetics portfolio sales reached $1.24 billion, down 0.1%. Global Botox Cosmetic revenues were&nbsp;$671 million, up 8.2%.</li>
</ul>
Dividend: AbbVie also increased its quarterly cash dividend from $1.55 per share to $1.64 per share, beginning with the dividend payable on Feb. 14, 2025, to shareholders of record as of Jan. 15, 2025.
Monday, AbbVie&nbsp;agreed to acquire Aliada Therapeutics for $1.4 billion&nbsp;in cash.
Aliada is a biotechnology company advancing therapies using a novel blood-brain barrier-crossing technology for the treatment of central nervous system diseases. Aliada&#8217;s lead investigational asset utilizing this delivery technology, ALIA-1758, is in development <a href="https://www.benzinga.com/pressreleases/24/10/n41571181/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-p" target="_blank" rel="noreferrer noopener">for Alzheimer&#8217;s disease</a>.
Guidance: AbbVie raised its 2024 adjusted EPS guidance to $10.90-$10.94 from <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992204/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growt" target="_blank" rel="noreferrer noopener">prior guidance of $10.67-$10.87</a> compared to consensus of $10.85, which includes an unfavorable impact of 64 cents per share related to acquired IPR&amp;D and milestones expense incurred year-to-date through the third quarter 2024.
In a conference call, AbbVie said it expects Skyrizi sales of $11.5 billion and Rinvoq sales of $5.8 billion in 2024.
Price Action: ABBV stock is up 1.8% at $192.95 at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41624533/caterpillar-q3-earnings-revenue-falls-short-of-expectations-ceo-anticipates-muted-china-demand" target="_blank" rel="noreferrer noopener">Caterpillar Q3 Earnings: Revenue Falls Short Of Expectations, CEO Anticipates Muted China Demand</a></li>
</ul>
Photo: Formatoriginal/Shutterstock.com

Guidance

Dividends

AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth

AbbVie Executive Says Company Cut 2024 U.S. Humira Sales Forecast By $400M To $7.4B To Reflect More Shift In Volume, Including To Skyrizi And Rinvoq

AbbVie Executive Says Now Expect Skyrizi Global Sales Of $11.5B And Rinvoq Sales Of $5.8B This Year

Abbvie Exec Says Company Now Seeing More Humira Molecule Volume Moving To Other Novel Mechanisms Than Previously Anticipated; Shift In Humira Volume Also Benefiting Skyrizi And Rinvoq Sales

AbbVie Raises Its Adjusted EPS Guidance For 2024 To $10.90-$10.94 From Prior Guidance Of $10.67-$10.87 Compared To Consensus Of $10.85

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.92 by 2.74 percent. The company reported quarterly sales of $14.46 billion which beat the analyst consensus estimate of $14.28 billion by 1.28 percent. This is a 3.83 percent increase over sales of $13.93 billion the same period last year.

AbbVie Q3 2024 Adj EPS $3.00 Beats $2.92 Estimate, Sales $14.46B Beat $14.28B Estimate

M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more

On 30 October, AbbVie (ABBV) increased its quarterly dividend by 5.81%, from $1.55 to $1.64 per share.

AbbVie Dividend Increase

Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November

As the global population ages, demand for healthcare solutions are expected to surge. As a result, investors might consider fundamentally solid healthcare stocks UnitedHealth Group, AbbVie, and Merck & Co., which are poised to benefit from the aging population boom. Keep reading... The rising global elderly population is driving increased demand for healthcare services, medications, and insurance, providing strong momentum for the healthcare sector. Coupled with rapid advancements in technology and new treatment innovations, the industry's outlook is more promising than ever.
Given this backdrop, it could be wise to consider investing in fundamentally sound healthcare companies like UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>), which are well-positioned to capitalize on this demographic shift.
A <a href="https://www.urban.org/policy-centers/cross-center-initiatives/program-retirement-policy/projects/data-warehouse/what-future-holds/us-population-aging">report projects</a> that by 2040, one in five Americans—totaling 80 million people—will be 65 or older. As the global population ages, the demand for biopharma products and advanced drugs to manage chronic diseases is set to grow significantly. The pharmaceuticals market is forecasted to generate $1.45 trillion in revenue by 2029, <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">exhibiting a CAGR of 4.7%</a>.
The health insurance market is expected to proliferate due to an aging population, increasing chronic diseases, and greater awareness of the financial benefits of health coverage. As per Precedence Research, the global health insurance market is anticipated to hit $5.12 trillion by 2034, growing at a <a href="https://precedenceresearch.com/health-insurance-market">CAGR of 7.4%</a>.
Considering these conducive trends, let's analyze the fundamentals of the three healthcare picks mentioned above.
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified healthcare company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and OptumRx.
On August 29, UNH and Goodwill Industries announced a partnership with a $4.5 million investment over three years to expand job training, health services, and workforce opportunities across 25 states, aiming to support access to better employment.
During the third quarter that ended September 30, 2024, UNH's total revenues increased 9.2% year-over-year to $100.82 billion. The company's earnings from operations came in at $8.71 billion, up 2.1% from the year-ago value. Moreover, its adjusted net earnings attributable to UNH common shareholders came in at $6.65 billion and $7.15 per share, up 8.4% and 9% from the previous year's quarter, respectively.
Street expects UNH's <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> and revenue for the quarter ending December 31, 2024, to increase 9.8% and 7.8% year-over-year to $6.76 and $101.79 billion, respectively. It surpassed Street EPS and revenue estimates in each of the trailing four quarters, which is remarkable.
Over the past year, the stock has gained 6.8% to close the last trading session at $565.79. It soared 7.6% year-to-date.
UNH's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
It has a B grade for Stability and Quality. It is ranked #5 out of 10 stocks in the A-rated <a href="https://stocknews.com/category/health-insurance/">Medical – Health Insurance</a> industry.
Click <a href="https://stocknews.com/stock/UNH/">here </a>to see UNH's ratings for Growth, Value, Momentum, and Sentiment.
AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV is a global diversified research-based biopharmaceutical company engaged in manufacturing and selling medications and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties.
On October 29, ABBV announced that Ontario would list VRAYLAR&#xAE; (cariprazine) as a General Benefit on its formulary starting October 31, 2024. This aims to improve access to mental health medication in Canada, where public coverage is crucial, as many individuals with serious mental illness face unemployment. VRAYLAR is already covered in Québec and by several federal programs for treating schizophrenia.
On October 28, the company would acquire Aliada Therapeutics, a biotech company developing blood-brain barrier-crossing technology to treat CNS diseases. Aliada's lead asset, ALIA-1758, is an antibody targeting Alzheimer's disease.
For the six-month period that ended on June 30, 2024, ABBV's net revenue increased 2.6% year-over-year to $26.77 billion, while the company's Neuroscience segment reported net revenue of $4.13 billion, indicating a 15.3% growth from the prior-year period. Its attributable net income came in at $2.74 billion, up 21% year-over-year, while its earnings per share attributable grew 21.4% from the year-ago value to $1.53.
ABBV raised its adjusted EPS guidance to range between $10.71 and $10.91 from the prior forecast of $10.61 and $10.81.
Analysts expect ABBV's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 2.6% and 5.5% year-over-year to $14.68 billion and $2.94, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters.
The stock climbed 22.3% year-to-date and 22.32% over the past year, to close the last trading session at $189.26.
ABBV's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
ABBV has a B grade for Growth, Value, Sentiment, Stability, and Quality. It is ranked #2 out of 163 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals </a>industry.
In addition to the POWR Ratings we've stated above, we also have ABBV ratings for Momentum. Get all ABBV ratings <a href="https://stocknews.com/stock/ABBV/">here</a>.
Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK operates as a healthcare company worldwide. It operates through two segments: Pharmaceutical and Animal Health. The company's offerings include global healthcare solutions in human health pharmaceuticals (oncology, immunology) and preventive vaccines. The Animal Health segment provides veterinary pharmaceuticals, vaccines, and digital health products.
On October 28, MRK announced that it and Moderna, Inc. (<a href="https://stocknews.com/stock/MRNA/">MRNA</a>) had initiated a Phase 3 trial, INTerpath-009, to evaluate V940 (mRNA-4157) combined with KEYTRUDA&#xAE; as an adjuvant treatment for resectable Stage II or III non-small cell lung cancer patients who did not achieve a complete response with prior therapies.
MRK's total sales rose 7.2% year-over-year to $16.11 billion for the second quarter that ended June 30, 2024. MRK's KEYTRUDA sales increased 15.9% year-over-year to $7.27 billion. Similarly, the company's non-GAAP net income and non-GAAP EPS were $5.81 billion and $2.28, compared to a non-GAAP net loss of $5.22 billion and $2.06 per share in the same quarter of the prior year, respectively.
Street expects MRK's revenue for the fourth quarter ending December 31, 2024, to increase 7.3% year-over-year to $15.70 billion. Its EPS for the same quarter is expected to grow considerably year-over-year to $1.91. It surpassed the Street EPS estimates in three of the trailing four quarters.
Shares of MRK have gained 0.6% over the past year, closing the last trading session at $104.20.
MRK's positive outlook is reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
MRK has an A grade for Quality and a B for Value and Stability. It is ranked #12 in the Medical – Pharmaceuticals industry.
To access additional ratings of MRK for Growth, Momentum, and Sentiment, <a href="https://stocknews.com/stock/MRK/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
UNH shares were trading at $562.07 per share on Tuesday afternoon, down $3.17 (-0.56%). Year-to-date, UNH has gained 8.02%, versus a 23.62% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/unh-abbv-mrk-3-healthcare-stocks-to-buy-for-an-aging-population-boom/>3 Healthcare Stocks to Buy for an Aging Population Boom</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Buy for an Aging Population Boom

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to find out… 2024 has been a breakout year for Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), with its shares surging nearly 56% year-to-date. This growth is largely driven by the company's blockbuster drugs in the diabetes and obesity markets, particularly Mounjaro and Zepbound. In addition, the recent FDA approval of its eczema drug, EBGLYSS, in September has garnered significant attention.
But with these wins under its belt, does Eli Lilly remain a top healthcare stock? Let's find out.
Lilly's latest win
On September 25, LLY received FDA approval for its new eczema treatment, <a href="https://investor.lilly.com/news-releases/news-release-details/new-data-show-lillys-ebglysstm-lebrikizumab-lbkz-provided">Ebglyss</a>. Unlike traditional topical treatments like creams or ointments, Ebglyss is an injectable designed for patients (aged 12 and older) with moderate-to-severe eczema who don't find relief with topical medications. This medication is a monthly injection that can be used on its own or alongside topical corticosteroids.
According to the company, about 16.5 million adults in the U.S. suffer from eczema, with roughly 40% experiencing severe symptoms such as cracked and bleeding skin, itchiness, and rashes. It reported that more than 80% of patients who received Ebglyss for three years were able to manage their eczema effectively.
Weight-Loss Market Expansion
Beyond dermatology, LLY continues to expand its footprint in the weight-loss market. On August 20, LLY announced that its weight-loss drug, tirzepatide, reduced the risk of developing type 2 diabetes by 94% among patients with prediabetes and obesity while also helping them lose an average of nearly 23% of their body weight.
Further, to make this weight-loss drug more accessible, LLY introduced a lower-cost version of tirzepatide under the brand name Zepbound, offering single-dose vials priced at least 50% below similar treatments on the market. This strategy could further expand its market reach and drive additional revenue growth.
Strong Financials
LLY's total revenue for the fiscal <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue">second quarter</a> (ended June 30, 2024) increased 36% year-over-year to $11.30 billion, driven by the sales of its diabetes and weight-loss drugs Mounjaro and Zepbound. Revenue from Lily's Verzenio also saw a substantial uptick, growing by 44% year-over-year to $1.33 billion.
Its non-GAAP gross margin also increased 40% from the year-ago value to $9.27 billion, while its operating income rose 74.7% from the prior-year quarter to $7.25 billion. Moreover, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> and earnings per share amounted to $3.54 billion and $3.92, representing an increase of 85.9% and 85.8%, respectively.
Buoyed by this strong performance, the company increased its full-year 2024 revenue guidance by $3 billion and non-GAAP EPS forecast by $2.60 to the range of $16.10 to $16.60. LLY also plans to bolster its production of diabetes and weight-loss drugs later this year.
Rosy Annual Forecasts
The consensus revenue estimate for the current year ending December 31, 2024, stands at $46.21 billion, signaling a 35.4% year-over-year increase. Moreover, the company's EPS is anticipated to witness an impressive 111.6% uptick from the previous year, reaching $13.37.
Looking ahead, analysts anticipate a 25.7% increase in revenue for the fiscal year 2025, with projections reaching $58.08 billion. Similarly, EPS for the next year is expected to grow 71.8% from the prior year, settling at $22.98.
POWR Ratings Show Promise
LLY's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall B rating, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. LLY has a B grade for Growth, which is consistent with its strong financial performance in the last reported quarter.
LLY is ranked #42 out of 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to access LLY's Value, Momentum, Stability, Sentiment, and Quality ratings.
Bottom Line
Beyond its success in weight management, the company is expanding its reach into areas like Alzheimer's, eczema, and even artificial intelligence. Moreover, the recent FDA approval of Ebglyss for eczema is yet another win, adding to LLY's growing portfolio of blockbuster drugs. With the global eczema market expected to <a href="https://www.globenewswire.com/en/news-release/2024/08/05/2924288/0/en/Global-Atopic-Dermatitis-Treatment-Market-to-expand-at-an-11-1-CAGR-from-2024-to-2034-totaling-USD-43-241-1-Million-Future-Market-Insights-Inc.html">more than double</a> by 2034, the company's new treatment has the potential to significantly boost revenue and keep the stock on its upward path.
Over the past year, the stock has gained 55.5% to close the last trading session at $909.15. Given this momentum, strong financials, and an optimistic outlook, we believe that adding LLY to your portfolio could be beneficial.
How Does Eli Lilly and Company (LLY) Stack Up Against Its Peers?
While LLY has an overall grade of B, equating to a Buy rating, you may also check out these other A-rated (Strong Buy) stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry: Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>), GSK plc (<a href="https://stocknews.com/stock/GSK/">GSK</a>) and AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>). To explore more medical pharmaceutical stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $896.45 per share on Wednesday afternoon, down $12.70 (-1.40%). Year-to-date, LLY has gained 54.53%, versus a 23.09% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/lly-nvs-gsk-abbv-is-eli-lilly-still-a-top-healthcare-stock-after-its/>Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Roblox, Peloton upgraded: Wall Street's top analyst calls

8 High-momentum stocks set for success – Oppenheimer

SDY: Dividend Growth ETF With High Turnover And Poor Return

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report), NeoGenomics (NEO ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)

SA Asks: How will the U.S. election results impact healthcare stocks?

AAPL

ALTR

AMKBY

AVTE

CASY

CHTR

DGRO

DGRW

EVRG

EWBC

FHLC

FLIC

FVRR

GLYC

GTES

KVUE

LANC

LECO

MSEX

MSTR

NCLH

NKTR

NOBL

OPCH

PARA

PTON

RARE

RBLX

REGL

SBUX

SIEGY

SMAWF

SPTM

SRCL

STZHF

TEVA

TRUE

TTWO

XLRE

ZBRA

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

TNXP

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process

AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline

SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM

AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario

AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Comments

AbbVie

AbbVie (ABBV) オプション

AbbVie (NYSE:ABBV) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル